Clinical and patient-reported outcomes with change from baseline to 6 months for patients with ≥80% adherence and <80% adherence
| Outcome | GLP1RA+basal insulin group | Basal-bolus insulin group | ||
| Month 6 to baseline | Month 6 to baseline | |||
| ≥80% adherence n=32 | <80% adherence n=22 | ≥80% adherence n=20 | <80% adherence n=36 | |
| HbA1c (%) | −4.41 (−5.23 to −3.59) | −3.63 (−4.68 to −2.58) | −3.61 (−4.63 to −2.59) | −2.60 (−3.46 to −1.74) |
| Weight (kg) | −1.3 (−3.2 to 0.67) | 0.31 (−2.2 to 2.9) | 4.6 (2.2 to 7.0) | 2.1 (0.1 to 4.0) |
| D-QOL | ||||
| General health perception | −0.94 (−1.27 to −0.60) | −0.78 (−1.19 to −0.36) | −0.35 (−0.77 to 0.07) | −0.30 (−0.66 to 0.06) |
| Treatment satisfaction | −0.59 (−0.86 to −0.32) | −0.65 (−0.98 to −0.31) | −0.25 (−0.59 to 0.08) | −0.25 (−0.55 to 0.04) |
| Hypoglycemia fear | −0.18 (−0.46 to 0.10) | −0.28 (−0.62 to 0.06) | 0.04 (−0.32 to 0.39) | 0.44 (0.14 to 0.75) |
Results are least squares mean change from baseline (95% CIs) from mixed effects linear models.
D-QOL, Diabetes Quality of Life Questionnaire; GLP1RA, glucagon-like peptide-1 receptor agonist.